217 related articles for article (PubMed ID: 18655904)
1. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
Chini B; Manning M; Guillon G
Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
[TBL] [Abstract][Full Text] [Related]
2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.
Tahara A; Tsukada J; Tomura Y; Wada Ki; Kusayama T; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 2000 Jan; 129(1):131-9. PubMed ID: 10694212
[TBL] [Abstract][Full Text] [Related]
4. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges.
Chini B; Manning M
Biochem Soc Trans; 2007 Aug; 35(Pt 4):737-41. PubMed ID: 17635137
[TBL] [Abstract][Full Text] [Related]
5. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
Frantz MC; Rodrigo J; Boudier L; Durroux T; Mouillac B; Hibert M
J Med Chem; 2010 Feb; 53(4):1546-62. PubMed ID: 20104850
[TBL] [Abstract][Full Text] [Related]
6. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
7. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
Guillon G; Derick S; Pena A; Cheng LL; Stoev S; Seyer R; Morgat JL; Barberis C; Gal CS; Wagnon J; Manning M
J Neuroendocrinol; 2004 Apr; 16(4):356-61. PubMed ID: 15089974
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
9. Non-peptide oxytocin agonists.
Pitt GR; Batt AR; Haigh RM; Penson AM; Robson PA; Rooker DP; Tartar AL; Trim JE; Yea CM; Roe MB
Bioorg Med Chem Lett; 2004 Sep; 14(17):4585-9. PubMed ID: 15357997
[TBL] [Abstract][Full Text] [Related]
10. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
Albizu L; Teppaz G; Seyer R; Bazin H; Ansanay H; Manning M; Mouillac B; Durroux T
J Med Chem; 2007 Oct; 50(20):4976-85. PubMed ID: 17850055
[TBL] [Abstract][Full Text] [Related]
11. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
Gimpl G; Postina R; Fahrenholz F; Reinheimer T
Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
[TBL] [Abstract][Full Text] [Related]
12. Discovery and design of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Recept Signal Transduct Res; 1999; 19(1-4):631-44. PubMed ID: 10071789
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Terrillon S; Cheng LL; Stoev S; Mouillac B; Barberis C; Manning M; Durroux T
J Med Chem; 2002 Jun; 45(12):2579-88. PubMed ID: 12036367
[TBL] [Abstract][Full Text] [Related]
14. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.
Hawtin SR; Ha SN; Pettibone DJ; Wheatley M
FEBS Lett; 2005 Jan; 579(2):349-56. PubMed ID: 15642343
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
Bellenie BR; Barton NP; Emmons AJ; Heer JP; Salvagno C
Bioorg Med Chem Lett; 2009 Feb; 19(3):990-4. PubMed ID: 19095447
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala.
Huber D; Veinante P; Stoop R
Science; 2005 Apr; 308(5719):245-8. PubMed ID: 15821089
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
[TBL] [Abstract][Full Text] [Related]
18. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
Slusarz MJ; Slusarz R; Ciarkowski J
Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
[TBL] [Abstract][Full Text] [Related]
19. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
Andrés M; Peña A; Derick S; Raufaste D; Trojnar J; Wisniewski K; Trueba M; Serradeil-Le Gal C; Guillon G
Eur J Pharmacol; 2004 Oct; 501(1-3):59-69. PubMed ID: 15464063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
